Hydroxychloroquine Chemoprophylaxis for COVID-19 Infection in High-risk Healthcare Workers.

NCT ID: NCT04370015

Last Updated: 2020-05-06

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 374 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-05-15
• Study Completion Date: 2020-10-15

Brief Summary

Healthcare personnel are at an increased risk of exposure to SARS-CoV-2 infection while handling such patients. Currently, there is no treatment available for SARS-CoV-2 and stringent preventive measures are advised to avoid or minimize risk of exposure to healthcare workers. There are in vitro studies available which show inhibition of corona virus by hydroxychloroquine, a widely-used agent against malaria and certain autoimmune conditions and of low-cost and limited toxicity. However, evidence regarding its effects in patients is limited. We plan to conduct a randomized controlled trial to evaluate the safety and potential prophylactic efficacy of hydroxychloroquine in preventing secondary SARS-CoV-2 infection among healthcare workers at high-risk of exposure while managing such patients.

Detailed Description

An interventional randomised control trial that will include 374 participants who will be healthcare workers at variable risks of exposure to SARS-CoV-2 while managing patients both suspected and confirmed with COVID-19 infection.Each participant will undergo detailed clinical evaluation to confirm eligibility, complete blood count, retinal imaging and ECG rhythm lead at baseline. A nasopharyngeal swab for reverse-transcriptase-polymerase chain reaction (RT-PCR) will also be taken. The enrolled participants will be randomised to two treatment arms with the experimental arm receiving Tab.Hydroxychloroquine (HCQ) 400mg twice a day on day 1 followed by 400mg weekly for 11 weeks. The placebo comparator arm will receive 2 tablets twice daily on day 1 followed by 2 tablets weekly for 11 weeks. The participants will be followed up via phone call weekly to ensure drug compliance, occurrence of drug-related side effects or respiratory symptoms. The final visit 4 will mark the end of study at 12 weeks from randomisation when a repeat nasopharyngeal swab for SARS-CoV-2 RT-PCR will be taken.The primary outcome measures will be prevention of SARS-CoV-2 infection as determined by a negative RT-PCR in the experimental arm at the end of 12 weeks and HCQ safety as determined by occurrence of adverse events.

Conditions

SARS-CoV-2; Healthcare Workers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: QUADRUPLE

Study Groups

Treatment group

Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with oral hydroxychloroquine 400 mg twice a day (four 200 mg tablets) on day 1 followed by 400mg (two 200 mg tablets) once a week for 11 weeks.

Group Type: EXPERIMENTAL

Hydroxychloroquine

Intervention Type: DRUG

Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with oral hydroxychloroquine 400 mg twice a day (four 200 mg tablets) on day 1 followed by 400mg (two 200 mg tablets) once a week for 11 weeks.

Control group

Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with placebo twice a day (four tablets) on day 1 followed by 2 tablets once a week for 11weeks.

Group Type: PLACEBO_COMPARATOR

Placebo oral tablet

Intervention Type: DRUG

• Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with placebo twice a day (four tablets) on day 1 followed by 2 tablets once a week for 11weeks.

Interventions

Hydroxychloroquine

Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with oral hydroxychloroquine 400 mg twice a day (four 200 mg tablets) on day 1 followed by 400mg (two 200 mg tablets) once a week for 11 weeks.

Intervention Type: DRUG

Placebo oral tablet

• Health care workers at high risk of contracting SARS-CoV-2 randomized to this arm will be treated with placebo twice a day (four tablets) on day 1 followed by 2 tablets once a week for 11weeks.

Intervention Type: DRUG

Other Intervention Names

HCQ

Eligibility Criteria

Inclusion Criteria

• Adult healthcare workers all genders ≥ 18 to ≤ 60 years of age upon study consent.
• Healthcare workers (doctors and nurses) at Services hospital, Lahore considered work at high-risk of SARS-CoV-2 exposure (defined below):

• Healthcare workers in Corona triage areas.
• Healthcare workers in Corona Isolation Units.
• Healthcare workers in Corona ICUs.
• Healthcare workers in general medical wards.
• Healthcare workers in general surgical wards.
• Healthcare workers in other units not directly dealing with suspected Corona patients e.g. Endocrinology department
• Afebrile with no constitutional symptoms.
• No household contact with confirmed active SARS-CoV-2 infection in the last 3 weeks.
• Negative PCR at visit 0.
• Willing and able to comply with scheduled visits, treatment plan, and other study procedures.
• Willing to not take any other medicines especially fluoroquinolones and macrolides for the duration of study.
• Signed informed consent, demonstrating that the subject understands the interventions required for the study and the purpose of the study.

Exclusion Criteria

• Participation in other investigational clinical trials for the treatment or prevention of SARS-CoV-2 infection within 30days.
• Subjects unwilling to practice at least one highly effective method of birth control for the duration of the study.
• Having a prior history of blood disorders such as aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia or prior history of glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.
• Having H/O skin disorders e.g. dermatitis, psoriasis or porphyria.
• Taking any of the following medication:

• Anti-arrythmic agents including digoxin.
• GI drugs including antacids, proton-pump inhibitors, cimetidine.
• Anti-cancer treatment including methotrexate, cyclosporin.
• Anti-diabetic agents including insulin.
• Corticosteroids.
• Drugs causing QT interval prolongation especially antidepressants, anti-epileptics and macrolides.
• Drugs affecting electrolyte balance including diuretics, laxatives.
• Drug allergies: 4-Aminoquinolines.
• Pre-existing retinopathy/maculopathy of the eye.
• Known chronic liver disease or cirrhosis, including hepatitis B and/or untreated hepatitis.
• Previous history of severe hypoglycaemia.
• Known case of renal disease.
• Untreated or uncontrolled active bacterial, fungal infection.
• Known or suspected active drug or alcohol abuse.
• Women who are pregnant or breastfeeding.
• Known hypersensitivity to any component of the study drug.
• A known history of prolonged QT syndrome or history of additional risk factors for arrythmias (e.g., heart failure, family history of Long QT Syndrome).
• Known H/O respiratory disorders e.g. asthma, chronic obstructive pulmonary disease.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Services Institute of Medical Sciences, Pakistan

OTHER_GOV

Sponsor Role: lead

Responsible Party

Dr. Saira Burney

Doctor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Saira Burney, FRCP (Edin)

Role: PRINCIPAL_INVESTIGATOR

SIMS

Central Contacts

Saira Burney, FRCP (Edin)

Role: CONTACT

dr_syra@hotmail.com

923014226617

Khadija I Khawaja, FCPS

Role: CONTACT

khadijairfan@gmail.com

923009495896

Other Identifiers

16082019

Identifier Type: -

Identifier Source: org_study_id